169 related articles for article (PubMed ID: 12592374)
1. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder.
Hussain SA; Ganesan R; Hiller L; Murray PG; el-Magraby MM; Young L; James ND
Br J Cancer; 2003 Feb; 88(4):586-92. PubMed ID: 12592374
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
[TBL] [Abstract][Full Text] [Related]
3. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
4. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.
Hussain SA; Ganesan R; Hiller L; Cooke PW; Murray P; Young LS; James ND
Oncol Rep; 2003; 10(3):571-6. PubMed ID: 12684626
[TBL] [Abstract][Full Text] [Related]
5. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer.
Matsumoto H; Wada T; Fukunaga K; Yoshihiro S; Matsuyama H; Naito K
Jpn J Clin Oncol; 2004 Mar; 34(3):124-30. PubMed ID: 15078907
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
7. [Expression of the bcl-2 and bax oncoprotein in TCC and its clinical significances].
Yang B; Gu F; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Oct; 35(10):602-4. PubMed ID: 10678049
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer.
Gazzaniga P; Gradilone A; Giuliani L; Gandini O; Silvestri I; Nofroni I; Saccani G; Frati L; Aglianò AM
Ann Oncol; 2003 Jan; 14(1):85-90. PubMed ID: 12488298
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Hussain SA; Palmer DH; Ganesan R; Hiller L; Gregory J; Murray PG; Pastorek J; Young L; James ND
Oncol Rep; 2004 May; 11(5):1005-10. PubMed ID: 15069539
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival.
Korkolopoulou P; Lazaris ACh; Konstantinidou AE; Kavantzas N; Patsouris E; Christodoulou P; Thomas-Tsagli E; Davaris P
Eur Urol; 2002 Mar; 41(3):274-83. PubMed ID: 12180228
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
12. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and bcl-2.
Amirghofran Z; Monabati A; Khezri A; Malek-Hosseini Z
Pathol Oncol Res; 2004; 10(3):154-8. PubMed ID: 15448751
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
15. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
[TBL] [Abstract][Full Text] [Related]
16. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
19. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
Glick SH; Howell LP; White RW
J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
